Integrating Multiple Stability Measurements Improves Early Biologics Testing

John Stenson of Malvern Panalytical argues that combining several stability assays on a single platform can increase both throughput and data quality for early‑stage biologics development.

He notes that monoclonal antibodies and other protein therapeutics are highly sensitive to variables such as pH, concentration, temperature, viscosity and buffer composition, making it essential to evaluate both conformational and colloidal stability in realistic test conditions.

Introducing stability testing earlier-between hit confirmation and lead nomination-allows teams to screen a broad candidate pool while the cost of discarding a problematic molecule remains low. This early insight helps avoid later‑stage failures that can waste time and money.

To make the approach practical, Stenson emphasizes the need to study many molecules at low concentrations across a wide range of buffers and environmental conditions, leveraging the integrated platform to handle the large experimental matrix efficiently.